Wolverine Trading’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $29.9M | Buy |
678,200
+106,800
| +19% | +$4.99M | 0.02% | 469 |
|
|
2025
Q2 | $26.5M | Buy |
+571,400
| New | +$28M | 0.03% | 384 |
|
|
2025
Q1 | – | Sell |
-718,300
| Closed | -$40.3M | – | 4779 |
|
|
2024
Q4 | $40.3M | Buy |
718,300
+77,600
| +12% | +$4.34M | 0.04% | 283 |
|
|
2024
Q3 | $32.6M | Buy |
640,700
+54,100
| +9% | +$2.54M | 0.03% | 305 |
|
|
2024
Q2 | $24.4M | Buy |
586,600
+182,800
| +45% | +$8.18M | 0.03% | 335 |
|
|
2024
Q1 | $21.9M | Sell |
403,800
-183,400
| -31% | -$9.34M | 0.02% | 393 |
|
|
2023
Q4 | $30.1M | Buy |
587,200
+183,000
| +45% | +$9.61M | 0.03% | 329 |
|
|
2023
Q3 | $23.5M | Buy |
404,200
+35,000
| +9% | +$2.14M | 0.02% | 323 |
|
|
2023
Q2 | $23.6M | Buy |
+369,200
| New | +$24.8M | 0.03% | 318 |
|
|
2022
Q4 | – | Sell |
-434,600
| Closed | -$31.2M | – | 4028 |
|
|
2022
Q3 | $31.2M | Buy |
434,600
+58,500
| +16% | +$4.24M | 0.05% | 209 |
|
|
2022
Q2 | $29.4M | Buy |
376,100
+3,400
| +0.9% | +$259K | 0.05% | 218 |
|
|
2022
Q1 | $27.5M | Sell |
372,700
-175,500
| -32% | -$11.8M | 0.04% | 335 |
|
|
2021
Q4 | $34.3M | Buy |
548,200
+4,500
| +0.8% | +$264K | 0.04% | 322 |
|
|
2021
Q3 | $33M | Buy |
543,700
+74,900
| +16% | +$4.93M | 0.04% | 350 |
|
|
2021
Q2 | $31.1M | Buy |
468,800
+125,600
| +37% | +$8.19M | 0.05% | 280 |
|
|
2021
Q1 | $21.7M | Sell |
343,200
-72,800
| -18% | -$4.53M | 0.03% | 371 |
|
|
2020
Q4 | $25.8M | Buy |
416,000
+79,900
| +24% | +$4.91M | 0.04% | 325 |
|
|
2020
Q3 | $20.1M | Sell |
336,100
-82,300
| -20% | -$4.95M | 0.05% | 297 |
|
|
2020
Q2 | $24.2M | Buy |
418,400
+119,000
| +40% | +$7.12M | 0.07% | 192 |
|
|
2020
Q1 | $16.3M | Sell |
299,400
-173,700
| -37% | -$10.6M | 0.05% | 283 |
|
|
2019
Q4 | $30.2M | Buy |
473,100
+244,000
| +107% | +$14M | 0.07% | 221 |
|
|
2019
Q3 | $11.5M | Buy |
229,100
+50,700
| +28% | +$2.38M | 0.03% | 465 |
|
|
2019
Q2 | $8.09M | Sell |
178,400
-678,100
| -79% | -$31.6M | 0.02% | 630 |
|
|
2019
Q1 | $40.9M | Buy |
856,500
+498,200
| +139% | +$24.8M | 0.12% | 117 |
|
|
2018
Q4 | $18.3M | Buy |
358,300
+159,300
| +80% | +$8.56M | 0.05% | 282 |
|
|
2018
Q3 | $12.4M | Sell |
199,000
-55,900
| -22% | -$3.32M | 0.03% | 469 |
|
|
2018
Q2 | $16.1M | Hold |
254,900
| – | – | 0.04% | 320 |
|
|
2018
Q1 | $16.1M | Sell |
254,900
-48,200
| -16% | -$3.1M | 0.04% | 320 |
|
|
2017
Q4 | $18.6M | Sell |
303,100
-63,000
| -17% | -$3.94M | 0.07% | 252 |
|
|
2017
Q3 | $23.3M | Buy |
366,100
+93,600
| +34% | +$5.47M | 0.09% | 190 |
|
|
2017
Q2 | $15.2M | Sell |
272,500
-90,400
| -25% | -$4.92M | 0.07% | 253 |
|
|
2017
Q1 | $20.1M | Buy |
362,900
+79,800
| +28% | +$4.38M | 0.11% | 179 |
|
|
2016
Q4 | $16.5M | Sell |
283,100
-69,800
| -20% | -$3.82M | 0.08% | 254 |
|
|
2016
Q3 | $19M | Buy |
352,900
+113,400
| +47% | +$7.28M | 0.09% | 234 |
|
|
2016
Q2 | $17.5M | Buy |
+239,500
| New | +$16.9M | 0.1% | 196 |
|
Other funds holding BMY
Wolverine Trading's BMY Position: Q3 2025 in Review
Wolverine Trading increased its Bristol-Myers Squibb (BMY) stake by 205% in Q3 2025, buying an estimated $3.02M and bringing the position to 96,318 shares worth $4.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1510.
Wolverine Trading first reported a position in BMY in Q2 2016 and has held it in 31 quarters since. The position peaked at $11.1M in Q1 2019. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Wolverine Trading held 96,318 shares of Bristol-Myers Squibb worth $4.25M as of Q3 2025.
- Wolverine Trading bought 64,734 Bristol-Myers Squibb shares in Q3 2025, an estimated $3.02M.
- Bristol-Myers Squibb made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1510 holding.
- Wolverine Trading first reported a position in Bristol-Myers Squibb in Q2 2016 and has held it in 31 quarters since.
- Wolverine Trading's Bristol-Myers Squibb position peaked at $11.1M in Q1 2019.
- 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.